EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations

EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations

Saved in:
Bibliographic Details
Published in:Value in health Vol. 26; no. 12; p. S187
Main Authors: Gomez Montero, M., Capone, C., Kroi, F., Wigfield, P., Dalibot, C., Robinson, P.
Format: Journal Article
Language:English
Published: 01-12-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1098-3015
DOI:10.1016/j.jval.2023.09.955